Rhopressa is expensive primarily because it is a brand-name drug with no generic alternative, protected by patents that don’t expire until 2034. Its retail price without insurance typically runs over $300 for a single small bottle, putting it among the pricier glaucoma eye drops on the market. Several factors stack on top of each other to keep the cost high: patent exclusivity, a novel mechanism unlike older generics, corporate acquisition costs, and inconsistent insurance coverage.
No Generic Exists, and Won’t Until 2034
The single biggest driver of Rhopressa’s price is patent protection. According to FDA records, the last qualifying patent on netarsudil (Rhopressa’s active ingredient) doesn’t expire until March 14, 2034. Until that date, no other manufacturer can legally produce a generic version, which means there’s zero price competition. For context, the most commonly prescribed first-line glaucoma drop, latanoprost, has been available as a generic for years and costs a fraction of Rhopressa’s price, often under $20 a bottle.
A First-in-Class Drug With Unique Biology
Rhopressa isn’t just another version of an existing glaucoma medication. It works through a mechanism no previous eye drop used, which contributed to significant research and development costs. Older glaucoma drugs lower eye pressure in one of two ways: they either reduce the amount of fluid the eye produces or increase drainage through a secondary pathway. Rhopressa does something different. It directly relaxes the trabecular meshwork, the eye’s primary drainage tissue, by inhibiting an enzyme called ROCK (Rho-associated kinase). This opens up the main outflow channel that gets clogged in glaucoma.
On top of that, it also blocks a norepinephrine transporter, which reduces fluid production, and lowers pressure in the tiny veins that drain the eye. That triple mechanism is unique among glaucoma treatments. Developing a first-in-class drug with a novel target costs more than reformulating an existing compound, and manufacturers price accordingly to recover that investment during the patent window.
Alcon’s Acquisition Added Financial Pressure
Rhopressa was originally developed by Aerie Pharmaceuticals, a smaller company focused entirely on eye care. In 2022, Alcon, one of the world’s largest eye care companies, acquired Aerie through a merger at $15.25 per share. When a large company buys a smaller one to gain control of its drug portfolio, the acquisition cost gets factored into the business model. Alcon needs Rhopressa and its related product Rocklatan to generate enough revenue to justify that purchase, which creates little incentive to lower the price while patent protection holds.
How It Compares to Cheaper Alternatives
Here’s the tricky part for patients: Rhopressa doesn’t actually lower eye pressure more than generic latanoprost. In head-to-head comparisons, latanoprost monotherapy reduced intraocular pressure slightly more than netarsudil alone after four to six weeks of treatment, with a difference of about 1 mmHg favoring latanoprost. So for many patients, the cheaper generic works just as well or better as a first-line treatment.
Where Rhopressa finds its niche is in patients who don’t respond adequately to standard drops. Studies show that anywhere from 4% to 25% of patients don’t get a meaningful pressure reduction from latanoprost alone. Because Rhopressa targets a completely different pathway, it can work for those non-responders or be added alongside other medications. Rocklatan, which combines netarsudil with latanoprost in one bottle, lowered pressure about 2.4 mmHg more than latanoprost alone at two weeks. But Rocklatan is also brand-name only and similarly expensive.
What You’ll Actually Pay With Insurance
Your out-of-pocket cost depends heavily on your specific insurance plan. On Medicare Advantage plans, Rhopressa typically lands on Tier 3 (preferred brand drugs), with copays around $47 for a 30-day supply at retail. A 90-day mail-order supply runs roughly $94, which is cheaper per month than picking it up at the pharmacy each time.
Data from a pharmacy partnership study found wide variation in what patients actually paid. About 40% of Rhopressa users paid $10 or less out of pocket, likely through manufacturer coupons or favorable insurance. Another 36% paid between $11 and $50. But roughly 19% of patients were stuck paying over $100 per fill. For Rocklatan, the distribution was similar, with 19% paying more than $100. Without any insurance or discount program, the cash price can exceed $300.
Ways to Reduce the Cost
If your doctor has prescribed Rhopressa and the price is a barrier, a few options can help. Alcon offers a manufacturer savings card that can significantly reduce copays for commercially insured patients. Some patients also find lower prices through pharmacy discount programs or by comparing prices across pharmacies, where costs can vary by $100 or more for the same bottle.
If cost remains prohibitive, it’s worth discussing alternatives with your eye doctor. For many patients, generic latanoprost or other generic prostaglandin drops achieve adequate pressure control at a fraction of the cost. Rhopressa is most valuable when those first-line treatments haven’t worked well enough on their own, so the cost question often comes down to whether the unique mechanism is clinically necessary for your specific situation.